283 related articles for article (PubMed ID: 31982607)
1. Hepatitis Flares Are Associated With Better Outcomes Than No Flare in Patients With Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection.
Chang ML; Cheng JS; Chien RN; Liaw YF
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2064-2072.e2. PubMed ID: 31982607
[TBL] [Abstract][Full Text] [Related]
2. The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients.
Liu YC; Jeng WJ; Peng CW; Chien RN; Liaw YF
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1533-1541.e11. PubMed ID: 36038130
[TBL] [Abstract][Full Text] [Related]
3. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study.
Hsu YC; Lin YH; Lee TY; Nguyen MH; Tseng CH; Ho HJ; Kao FY; Lin JT; Wu CY; Wu CY
Aliment Pharmacol Ther; 2023 Aug; 58(4):463-473. PubMed ID: 37341016
[TBL] [Abstract][Full Text] [Related]
4. Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.
Brahmania M; Lombardero M; Hansen BE; Terrault NA; Lok AS; Perrillo RP; Belle SH; Di Bisceglie AM; Feld JJ; Lee WM; Fried MW; Janssen HLA;
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2541-2551.e2. PubMed ID: 30743006
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management.
Chang ML; Liaw YF
J Hepatol; 2014 Dec; 61(6):1407-17. PubMed ID: 25178562
[TBL] [Abstract][Full Text] [Related]
6. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
7. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
Wong D; Littlejohn M; Edwards R; Jackson K; Revill P; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti-Ferret M; Janssen H; Gane E; Locarnini S; Thompson A
Liver Int; 2018 Oct; 38(10):1760-1769. PubMed ID: 29427368
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of clinical characteristics of persistent HBeAg positivity in patients with chronic hepatitis B treated with nucleos(t)ide analogues].
Peng LP; Gan WQ; Zheng YB; Chen YM; Liu J; Wu ZB; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2024 Mar; 32(3):193-200. PubMed ID: 38584099
[No Abstract] [Full Text] [Related]
9. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
10. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
11. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
12. Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B.
Liem KS; Chi H; Fung S; Wong DK; Yim C; Noureldin S; Chen J; de Man RA; Sarowar A; Feld JJ; Hansen BE; Hou J; Peng J; Janssen HLA
J Viral Hepat; 2022 Nov; 29(11):986-993. PubMed ID: 36048970
[TBL] [Abstract][Full Text] [Related]
13. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
14. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
15. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
16. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.
Kumada T; Toyoda H; Yasuda S; Miyake N; Ito T; Tanaka J
J Viral Hepat; 2021 Mar; 28(3):508-516. PubMed ID: 33306854
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
19. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B flare: the good, the bad and the ugly.
Liaw YF
Expert Rev Gastroenterol Hepatol; 2022; 16(11-12):1043-1051. PubMed ID: 36476208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
